Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome.

Nasrin Aktar, Ahmed Moudud, Tingting Chen, Xiaoqing Gao, Hanhui Min, Meng Tang, Xiaohui Zhou

Current pharmaceutical design 2021

filter terms:

Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction, and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically. These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Nasrin Aktar, Ahmed Moudud, Tingting Chen, Xiaoqing Gao, Hanhui Min, Meng Tang, Xiaohui Zhou. Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome. Current pharmaceutical design. 2021;27(25):2861-2871